Delta-radiomics features for predicting the major pathological response to neoadjuvant chemoimmunotherapy in non-small cell lung cancer
Objectives To investigate if delta-radiomics features have the potential to predict the major pathological response (MPR) to neoadjuvant chemoimmunotherapy in non-small cell lung cancer (NSCLC) patients. Methods Two hundred six stage IIA-IIIB NSCLC patients from three institutions (Database1 = 164; Database2 = 21; Database3 = 21) who received neoadjuvant chemoimmunotherapy and surgery were included. Patients in Database1 were randomly assigned to the training dataset and test dataset, with a ratio of 0.7:0.3. Patients in Database2 and Database3 were used as two independent external validation datasets. Contrast-enhanced CT scans were obtained at baseline and before surgery. The delta-radiomics features were defined as the relative net change of radiomics features between baseline and preoperative. The delta-radiomics model and pre-treatment radiomics model were established. The performance of Immune-Related Response Evaluation Criteria in Solid Tumors (iRECIST) for predicting MPR was also evaluated. Results Half of the patients (106/206, 51.5%) showed MPR after neoadjuvant chemoimmunotherapy. For predicting MPR, the delta-radiomics model achieved a satisfying area under the curves (AUCs) values of 0.768, 0.732, 0.833, and 0.716 in the training, test, and two external validation databases, respectively, which showed a superior predictive performance than the pre-treatment radiomics model (0.644, 0.616, 0.475, and 0.608). Compared with iRECIST criteria (0.624, 0.572, 0.650, and 0.466), a mixed model that combines delta-radiomics features and iRECIST had higher AUC values for MPR prediction of 0.777, 0.761, 0.850, and 0.670 in four sets. Conclusion The delta-radiomics model demonstrated superior diagnostic performance compared to pre-treatment radiomics model and iRECIST criteria in predicting MPR preoperatively in neoadjuvant chemoimmunotherapy for stage II-III NSCLC. Clinical relevance statement Delta-radiomics features based on the relative net change of radiomics features between baseline and preoperative CT scans serve a vital support tool in accurately identifying responses to neoadjuvant chemoimmunotherapy, which can help physicians make more appropriate treatment decisions. Key Points • The performances of pre-treatment radiomics model and iRECIST model in predicting major pathological response of neoadjuvant chemoimmunotherapy were unsatisfactory. • The delta-radiomics features based on relative net change of radiomics features between baseline and preoperative CT scans may be used as a noninvasive biomarker for predicting major pathological response of neoadjuvant chemoimmunotherapy. • Combining delta-radiomics features and iRECIST can further improve the predictive performance of responses to neoadjuvant chemoimmunotherapy..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:34 |
|---|---|
| Enthalten in: |
European radiology - 34(2023), 4 vom: 22. Sept., Seite 2716-2726 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Han, Xiaoyu [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| BKL: | |
|---|---|
| Themen: |
Area under the curve |
| Anmerkungen: |
© The Author(s), under exclusive licence to European Society of Radiology 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. |
|---|
| doi: |
10.1007/s00330-023-10241-x |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR055234992 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR055234992 | ||
| 003 | DE-627 | ||
| 005 | 20240322064643.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240322s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s00330-023-10241-x |2 doi | |
| 035 | |a (DE-627)SPR055234992 | ||
| 035 | |a (SPR)s00330-023-10241-x-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q VZ |
| 084 | |a 44.64 |2 bkl | ||
| 100 | 1 | |a Han, Xiaoyu |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Delta-radiomics features for predicting the major pathological response to neoadjuvant chemoimmunotherapy in non-small cell lung cancer |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © The Author(s), under exclusive licence to European Society of Radiology 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. | ||
| 520 | |a Objectives To investigate if delta-radiomics features have the potential to predict the major pathological response (MPR) to neoadjuvant chemoimmunotherapy in non-small cell lung cancer (NSCLC) patients. Methods Two hundred six stage IIA-IIIB NSCLC patients from three institutions (Database1 = 164; Database2 = 21; Database3 = 21) who received neoadjuvant chemoimmunotherapy and surgery were included. Patients in Database1 were randomly assigned to the training dataset and test dataset, with a ratio of 0.7:0.3. Patients in Database2 and Database3 were used as two independent external validation datasets. Contrast-enhanced CT scans were obtained at baseline and before surgery. The delta-radiomics features were defined as the relative net change of radiomics features between baseline and preoperative. The delta-radiomics model and pre-treatment radiomics model were established. The performance of Immune-Related Response Evaluation Criteria in Solid Tumors (iRECIST) for predicting MPR was also evaluated. Results Half of the patients (106/206, 51.5%) showed MPR after neoadjuvant chemoimmunotherapy. For predicting MPR, the delta-radiomics model achieved a satisfying area under the curves (AUCs) values of 0.768, 0.732, 0.833, and 0.716 in the training, test, and two external validation databases, respectively, which showed a superior predictive performance than the pre-treatment radiomics model (0.644, 0.616, 0.475, and 0.608). Compared with iRECIST criteria (0.624, 0.572, 0.650, and 0.466), a mixed model that combines delta-radiomics features and iRECIST had higher AUC values for MPR prediction of 0.777, 0.761, 0.850, and 0.670 in four sets. Conclusion The delta-radiomics model demonstrated superior diagnostic performance compared to pre-treatment radiomics model and iRECIST criteria in predicting MPR preoperatively in neoadjuvant chemoimmunotherapy for stage II-III NSCLC. Clinical relevance statement Delta-radiomics features based on the relative net change of radiomics features between baseline and preoperative CT scans serve a vital support tool in accurately identifying responses to neoadjuvant chemoimmunotherapy, which can help physicians make more appropriate treatment decisions. Key Points • The performances of pre-treatment radiomics model and iRECIST model in predicting major pathological response of neoadjuvant chemoimmunotherapy were unsatisfactory. • The delta-radiomics features based on relative net change of radiomics features between baseline and preoperative CT scans may be used as a noninvasive biomarker for predicting major pathological response of neoadjuvant chemoimmunotherapy. • Combining delta-radiomics features and iRECIST can further improve the predictive performance of responses to neoadjuvant chemoimmunotherapy. | ||
| 650 | 4 | |a Humans |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Carcinoma, non-small-cell lung |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Neoadjuvant therapy |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Area under the curve |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Response Evaluation Criteria in Solid Tumors |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Wang, Mingliang |4 aut | |
| 700 | 1 | |a Zheng, Yuting |4 aut | |
| 700 | 1 | |a Wang, Na |4 aut | |
| 700 | 1 | |a Wu, Ying |4 aut | |
| 700 | 1 | |a Ding, Chengyu |4 aut | |
| 700 | 1 | |a Jia, Xi |4 aut | |
| 700 | 1 | |a Yang, Ran |4 aut | |
| 700 | 1 | |a Geng, Mingfei |4 aut | |
| 700 | 1 | |a Chen, Zhen |4 aut | |
| 700 | 1 | |a Zhang, Songlin |4 aut | |
| 700 | 1 | |a Zhang, Kailu |4 aut | |
| 700 | 1 | |a Li, Yumin |4 aut | |
| 700 | 1 | |a Liu, Jia |4 aut | |
| 700 | 1 | |a Gu, Jin |4 aut | |
| 700 | 1 | |a Liao, Yongde |4 aut | |
| 700 | 1 | |a Fan, Jun |4 aut | |
| 700 | 1 | |a Shi, Heshui |0 (orcid)0000-0001-7644-3711 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European radiology |d Springer Berlin Heidelberg, 1991 |g 34(2023), 4 vom: 22. Sept., Seite 2716-2726 |w (DE-627)SPR00395112X |w (DE-600)1472718-3 |x 1432-1084 |7 nnns |
| 773 | 1 | 8 | |g volume:34 |g year:2023 |g number:4 |g day:22 |g month:09 |g pages:2716-2726 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/s00330-023-10241-x |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_SPRINGER | ||
| 912 | |a SSG-OLC-PHA | ||
| 936 | b | k | |a 44.64 |q VZ |
| 951 | |a AR | ||
| 952 | |d 34 |j 2023 |e 4 |b 22 |c 09 |h 2716-2726 | ||